Tozorakimab Targeting Interleukin-33 for COPD: A New Paradigm of Upstream Inflammation Intervention

Chronic obstructive pulmonary disease (COPD) is one of the leading causes of mortality and disability worldwide. It is characterized by persistent airflow limitation, chronic inflammation, and recurrent acute exacerbations.

Although inhaled therapies—such as bronchodilators and corticosteroids—can relieve symptoms, disease progression and exacerbations remain difficult to control for many patients. As a result, biologics targeting key inflammatory pathways have become a major focus of research. Among them, Tozorakimab has emerged as a highly promising innovative therapy.

1. The Inflammatory Nature of COPD: Why Target “Upstream” Signals?

The pathological core of COPD lies in chronic inflammation, particularly driven by “alarmins” released after airway epithelial damage. Among these, interleukin-33 (IL-33) is considered a key upstream mediator.

IL-33 plays critical roles in:

●  Activating innate immune responses (e.g., ILC2 cells)

●  Promoting type 2 (Th2) inflammation

●  Increasing mucus production in airways

●  Worsening airway remodeling and tissue damage

As an upstream inflammatory signal, IL-33 amplifies multiple downstream pathways once activated. Therefore, therapies targeting downstream cytokines often show limited efficacy, while directly blocking IL-33 offers the potential for source-level control. This marks a shift in COPD treatment—from symptom management to mechanism-based intervention.

2. Tozorakimab: A Precise Blocker of the IL-33 Pathway

Tozorakimab is a monoclonal antibody targeting IL-33. What distinguishes it is its ability to bind both the reduced (active) and oxidized (inactive but reactivatable) forms of IL-33, enabling more comprehensive pathway inhibition.

Its mechanisms include:

●  Blocking IL-33 binding to the ST2 receptor

●  Inhibiting IL-33 signaling via the RAGE/EGFR pathway

●  Simultaneously suppressing multiple inflammatory amplification routes

This dual-pathway inhibition sets it apart from traditional therapies that target a single receptor, giving Tozorakimab broader anti-inflammatory potential. It functions not just as an anti-inflammatory drug, but as a regulator of the inflammatory network.

3. Mechanism of Action: How Does It Improve COPD Pathology?

Tozorakimab exerts therapeutic effects in COPD through multiple layers of action:

1️⃣ Suppression of inflammatory cascades

By blocking IL-33 signaling, it reduces the release of cytokines such as IL-5 and IL-13, lowering airway inflammation.

2️⃣ Improvement of airway epithelial function

Studies suggest it helps restore airway epithelial integrity and enhances “club cell” function, improving tissue repair capacity.

3️⃣ Reduction of mucus hypersecretion

Since IL-33 is closely linked to mucus overproduction, blocking this pathway helps break the cycle of inflammation–mucus–obstruction.

4️⃣ Enhancement of antiviral defense

COPD exacerbations are often triggered by viral infections. By modulating IL-33-related immune responses, Tozorakimab improves antiviral immunity.

Overall, this therapy goes beyond simple inflammation control—it reconstructs the interplay between inflammation, immunity, and epithelial function.

4. Clinical Progress: Phase III Trials Validate Efficacy

Multiple Phase III clinical trials reported in 2026 (including OBERON, TITANIA, and MIRANDA) have demonstrated:

●  Significant reduction in moderate-to-severe exacerbation rates

●  Efficacy in both former smokers and the general COPD population

●  Benefits across patients with varying eosinophil levels

●  Consistent outcomes across different stages of lung function

Moreover, when used as an add-on to standard inhaled therapy, Tozorakimab further improves patient outcomes.

These findings suggest that the IL-33 pathway may serve as a cross-phenotype therapeutic target, rather than being limited to specific patient subgroups.

5. How Does It Compare to Traditional Biologics?

Existing biologics in COPD (e.g., anti-IL-5, anti-IL-4/13) typically target downstream inflammatory mediators and are effective only in selected populations.

In contrast, Tozorakimab offers broader advantages:

Thus, Tozorakimab represents a shift from precision subtyping to broad mechanism-based intervention.

6. Clinical Significance: A New Treatment Paradigm

The emergence of Tozorakimab may reshape COPD treatment in several ways:

✔ From symptom relief to reduction of exacerbations

✔ From bronchodilation to upstream inflammation control

✔ From phenotype-specific therapy to universal target strategies

✔ From short-term management to long-term disease modification

This signals the arrival of the biologics era in COPD.

7. Challenges and Future Directions

Despite its promise, several challenges remain:

●  Variability of IL-33 pathway activity among patients

●  Need for long-term safety data

●  Cost and accessibility concerns

●  Optimization of combination therapy strategies

Future research directions include:

●  Combination with immunomodulatory therapies

●  Biomarker-driven patient selection

●  Personalized dosing strategies

●  Expansion into asthma and other inflammatory diseases

These factors will determine whether Tozorakimab can become a standard therapy for COPD.

Conclusion

Targeting IL-33 with Tozorakimab introduces a fundamentally new approach to COPD treatment—intervening at the source of inflammation and systematically reshaping the airway immune environment. With continued validation from Phase III trials, it has the potential to become one of the first broadly applicable biologics in COPD.

As understanding of the IL-33 pathway deepens and precision medicine advances, COPD management is expected to evolve from disease control to disease modification, ushering in a new era for chronic respiratory care. Looking ahead, Dengyue Pharma is committed to professionalism, compliance, and innovation, building a trusted platform that connects patients worldwide with cutting-edge therapies.